Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Nautilus Biotechnology (NASDAQ: NAUT) launched an Early Access Program on Jan 8, 2026 to provide select researchers with initial access to its single-molecule proteomics platform using the company's Iterative Mapping method, beginning with a validated tau proteoforms assay.
The program offers exclusive use for an initial group, support for data interpretation and custom assay development, and aims to accelerate Alzheimer’s and neurodegenerative research. A Nautilus preprint and early external deployment at the Buck Institute reported mapping of up to 768 distinct tau proteoforms across brain regions, and the company will host a webinar on Jan 14, 2026 to present updated collaboration data.
Nautilus (NASDAQ: NAUT) installed and tested its first external field evaluation unit at the Buck Institute, running the instrument for more than 6 months on neurodegenerative disease samples and producing highly reproducible end-to-end data across sites and users.
The unit uses Nautilus’ Iterative Mapping approach and a proprietary tau proteoform assay that quantifies 768 proteoform groups. Results will be presented at the HUPO World Congress on Nov 10, 2025, and may support future joint publications.
Nautilus Biotechnology (NASDAQ: NAUT) reported third quarter 2025 results for the period ended September 30, 2025. Key operational milestones include continued processing of Tau proteoform samples with collaborators and progress on a broadscale assay format intended to support a commercial launch in late 2026. The company expects an early access program for Tau proteoforms in the first half of 2026 and plans to share collaborator data at the upcoming World HUPO conference.
Financial highlights: Operating expenses were $15.5 million in Q3 2025, down 19% year-over-year; net loss was $13.6 million versus $16.4 million a year earlier; and cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025. A conference call and webcast were scheduled for October 28, 2025 at 5:30 AM PT.
Nautilus Biotechnology (NASDAQ: NAUT) will report third quarter 2025 financial results before market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Live audio will be available on the company’s Investors website at www.nautilus.bio. Investors can listen to the webcast for prepared remarks and management Q&A covering the quarter’s performance and near‑term plans.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 8th at 1:50 PM ET. Additionally, management will present at the Q3 Investor Summit Group Virtual Conference on September 16th at 1:00 PM ET, with one-on-one meetings scheduled for September 17th.
Webcasts of both presentations will be accessible through the Investors section of Nautilus's website.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2025 financial results, highlighting significant progress in its single-molecule proteome analysis platform development. The company published its first scientific manuscript demonstrating the Iterative Mapping method for measuring proteoforms with unprecedented resolution. Additionally, Nautilus secured two new collaborations with research institutes focusing on Tau proteoform studies in Alzheimer's disease research.
Financial results showed operating expenses of $17.1 million, an 18% decrease from $20.8 million in Q2 2024. The company reported a net loss of $15.0 million, improved from $18.0 million year-over-year. Cash, cash equivalents, and investments stood at $179.5 million as of June 30, 2025.
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic agreement with the Allen Institute to investigate the relationship between tau protein and Alzheimer's disease using Nautilus' Iterative Mapping technology. The collaboration aims to identify and analyze tau proteoforms from human brain tissue to better understand their role in neurodegenerative conditions.
The partnership follows Nautilus' recent preprint demonstrating their single-molecule proteomics platform's capabilities in analyzing tau proteoforms with unprecedented resolution. The technology has shown promising results in studying brain samples from both cognitively normal and impaired Alzheimer's patients, validating the platform's accuracy, sensitivity, and reproducibility.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has scheduled its Q2 2025 financial results announcement for July 31, 2025, before market open.
The company will host a conference call and webcast at 5:30 AM PT / 8:30 AM ET to discuss quarterly results, business developments, and future outlook. Investors can access the live webcast through the company's website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 10, 2025, at 2:00 p.m. Eastern Time. Investors and interested parties can access both live and archived webcasts of the presentation through the "Investors" section on Nautilus' website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) has released its Q1 2025 financial results, highlighting progress in their single-molecule proteome analysis platform. CEO Sujal Patel reported positive developments in their Tau proteoform assay, with performance metrics meeting launch specifications and customer requirements.
Key financial highlights:
- Operating expenses: $18.8 million, down 13% from $21.6 million in Q1 2024
- Net loss: $16.6 million, improved from $18.7 million in Q1 2024
- Cash position: $192.8 million in cash, cash equivalents, and investments as of March 31, 2025
The company's cost reduction stems from optimized operations, timing of R&D activities, reduced stock-based compensation, and lower professional services costs. Nautilus aims to enable researchers to study Tau proteoforms in Alzheimer's and other neurodegenerative diseases throughout 2025.
FAQ
What is the current stock price of Nautilus Biotechnology (NAUT)?
What is the market cap of Nautilus Biotechnology (NAUT)?
